

116TH CONGRESS
2D SESSION

H. R. 6261

To provide for coverage of testing for COVID-19 at no cost sharing for Indians receiving health services through the Indian Health Service, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

MARCH 12, 2020

Mr. RUIZ introduced the following bill; which was referred to the Committee on Natural Resources, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned

A BILL

To provide for coverage of testing for COVID-19 at no cost sharing for Indians receiving health services through the Indian Health Service, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. COVERAGE OF TESTING FOR COVID-19 AT NO**
4 **COST SHARING FOR INDIANS RECEIVING**
5 **HEALTH SERVICES THROUGH INDIAN**
6 **HEALTH SERVICE.**

7 The Secretary of Health and Human Services shall
8 cover, without the imposition of any cost sharing require-

1 ments, the cost of providing the following items and serv-
2 ices furnished during any portion of the emergency period
3 defined in paragraph (1)(B) of section 1135(g) of the So-
4 cial Security Act (42 U.S.C. 1320b–5(g)) beginning on or
5 after the date of the enactment of this Act to Indians (as
6 defined in section 4 of the Indian Health Care Improve-
7 ment Act (25 U.S.C. 1603)) receiving health services
8 through the Indian Health Service, regardless of whether
9 such items or services have been authorized under the con-
10 tract health services system funded by the Indian Health
11 Service or are covered as a health service of the Indian
12 Health Service:

13 (1) In vitro diagnostic products (as defined in
14 section 809.3(a) of title 21, Code of Federal Regula-
15 tions) for the detection of SARS–CoV–2 or the diag-
16 nosis of the virus that causes COVID-19 that are
17 approved, cleared, or authorized under section
18 510(k), 513, 515, or 564 of the Federal Food,
19 Drug, and Cosmetic Act, and the administration of
20 such in vitro diagnostic products.

21 (2) Health care provider office visits, urgent
22 care center visits, and emergency room visits relat-
23 ing to testing for COVID-19.

○